CYPROTERONE ACETATE; 427-51-0; Androcur; Cyproterone 17-O-acetate; Cyproteroneacetate; Cyproteron acetate; Cyproteron-R acetate; SH 714; Cyprostat; NSC-81430; Cyprosterone acetate; SH-714; SH 80714; 4KM2BN5JHF; Cyproterone 17.alpha.-acetate; CHEMBL139835; 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-; DTXSID5020366; CHEBI:50743; NSC81430; 6-Chloro-1beta,2beta-dihydro-17-hydroxy-3'H-cyclopropa(1,2)-pregna-1,4,6-triene-3,20-dione acetate; NCGC00091032-03; (1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate; 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1.beta.,2.beta.)-; DTXCID30366; Cyproterone (acetate); 6-chloro-3,20-dioxo-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-dien-17-yl acetate; (2aR,3aS,3bS,3cS,5aS,6R,8aS,8bR)-6-acetyl-10-chloro-3b,5a-dimethyl-2-oxo-2,2a,3,3a,3b,3c,4,5,5a,6,7,8,8a,8b-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-6-yl acetate; SMR000326769; CCRIS 4385; HSDB 3592; SR-01000075755; EINECS 207-048-3; UNII-4KM2BN5JHF; NSC 81430; Cyprostat&reg; cyproterone-acetate; (1?,2?)-17-(Acetyloxy)-6-chloro-1,2-dihydro-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione; 3'H-CYCLOPROPA(1,2)PREGNA-1,4,6-TRIENE-3,20-DIONE, 17-(ACETYLOXY)-6-CHLORO-1,2-DIHYDRO-, (1.BETA.,2.BETA.)-; CAS-427-51-0; MFCD00864671; 2oz7; 6-Chloro-delta-6-1,2alpha-methylene-17alpha-hydroxyprogesterone acetate; 1,2-alpha-Methylene-6-chloro-delta(sup 6)-17-alpha-hydroxyprogesterone acetate; 1,2-alpha-Methylene-6-chloro-pregna-4,6-diene-3,20-dione 17-alpha-acetate; 6-Chloro-1,2-alpha-methylene-6-dehydro-17-alpha-hydroxyprogesterone acetate; 6-Chloro-delta(sup 6)-1,2-alpha-methylene-17-alpha-hydroxyprogesterone acetate; cid_9880; SCHEMBL5936; 1,2-alpha-Methylene-6-chloro-(sup 4,6)-pregnadiene-17-alpha-ol-3,20-dione 17-alpha-acetate; 17-alpha-Acetoxy-6-chloro-1-alpha,2-alpha-methylenepregna-4,6-diene-3,20-dione; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteronacetat [German]; 6-Chloro-1,2-alpha-methylene-17-alpha-hydroxy-delta(sup 6)-progesterone acetate; 6-Chloro-17-hydroxy-1-alpha,2-alpha-methylenepregna-4,6-diene-3,20-dione acetate; Pregna-4,6-diene-3,20-dione, 6-chloro-17-hydroxy-1-alpha,2-alpha-methylene-, acetate; BIDD:PXR0052; Lopac0_000301; MLS000859908; MLS001055462; MLS001066353; MLS002207305; MLS006011110; Cyproterone acetate, >=98%; (non-d)Cyproterone acetate-d5; GTPL2865; CYPROTERONE ACETATE [MI]; CYPROTERONE ACETATE [JAN]; Cyproterone acetate Assay Standard; CYPROTERONE ACETATE [HSDB]; CYPROTERONE ACETATE [USAN]; HMS2090A14; HMS2233J06; HMS3260N04; CYPROTERONE ACETATE [MART.]; ZINC3814423; Tox21_111064; Tox21_201686; Tox21_302941; Tox21_500301; AC-929; BDBM50094569; CYPROTERONE ACETATE [WHO-DD]; DL-368; s2042; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteronacetat; AKOS008901350; AKOS015895238; Tox21_111064_1; CCG-204396; DB04839; LP00301; SDCCGSBI-0050289.P002; NCGC00091032-01; NCGC00091032-04; NCGC00091032-05; NCGC00091032-09; NCGC00091032-12; NCGC00256442-01; NCGC00259235-01; NCGC00260986-01; NCGC00262575-02; Progesterone,2.alpha.-methylene, acetate; (1S,2S,3S,12S,16S,5R,11R,15R)-15-acetyl-9-chloro-2,16-dimethyl-6-oxopentacyclo [9.7.0.0<2,8>.0<3,5>.0<12,16>]octadeca-7,9-dien-15-yl acetate; 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 6-chloro-1-beta,2-beta-dihydro-17-hydroxy-, acetate; 6-Chloro-1-beta,2-beta-dihydro-17-hydroxy-3'H-cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione 17-acetate; CYPROTERONE ACETATE [EP MONOGRAPH]; SMR000686068; Cyproterone acetate for peak identification; Progesterone,2.alpha.-methylene-, acetate; (acetyl-chloro-dimethyl-oxo-[?]yl) acetate; 1,6-diene-3,20-dione 17.alpha.-acetate; EU-0100301; C 3412; D01368; AB00698312-08; 1,6)-pregnadeine-17.alpha.-3,20-dione acetate; EN300-19765943; Q426185; SR-01000075755-1; SR-01000075755-4; SR-01000075755-6; W-106262; 1,6)-pregnadiene-17.alpha.-ol-3,20-dione acetate; BRD-K41141507-001-16-2; WLN: L F3 E6 D665 IV JU LUTJ A1 E1 RV1 RQ; 17.alpha.-Acetoxy-6-chloro-1.alpha.,6-diene-3,20-dione; 6-Chloro-17-hydroxy-1.alpha.,6-diene-3,20-dione acetate; 1,6)-pregnadiene-17.alpha.-ol-3,20-dione 17alpha-acetate; 6-Chloro-1.beta.,2]pregna-1,4,6-triene-3,20-dione acetate; Cyproterone acetate, European Pharmacopoeia (EP) Reference Standard; 6-chloro-17-acetoxy-1alpha,2alpha-methylene-4,6-pregnadiene-3,20-dione; 1,2.alpha.-Methylene-6-chloro-.delta.(sup 6)-17.alpha.-hydroxyprogesterone acetate; 17alpha-acetoxy-6-chloro-1alpha,2alpha-methylene-4,6-pregnadiene-3,20-dione; 6-Chloro-.delta.(sup 6)-1,2.alpha.-methylene-17.alpha.-hydroxyprogesterone acetate; 6-Chloro-1,2.alpha.-methylene-17.alpha.-hydroxy-.delta.(sup 6)-progesterone acetate; 6-Chloro-1,2.alpha.-methylene-6-dehydro-17.alpha.-hydroxyprogesterone acetate; Cyproterone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard; Pregna-4,20-dione, 6-chloro-17-hydroxy-1.alpha.,2.alpha.-methylene-, acetate; (1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxopentacyclo[9.7.0.0^{2,8}.0^{3,5}.0^{12,16}]octadeca-7,9-dien-15-yl acetate; 3'H-Cyclopropa[1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1.beta.,2.beta.)-; 3'H-Cyclopropa[1,4,6-triene-3,20-dione, 6-chloro-1.beta.,2.beta.-dihydro-17-hydroxy-, acetate; 3'H-Cyclopropa[1,4,6-triene-3,20-dione, 6-chloro-1.beta.,2.beta.-dihydro-17-hydroxy-,acetate; 6-CHLORO-1.BETA.,2.BETA.-DIHYDRO-17-HYDROXY-3'H-CYCLOPROPA(1,2)-PREGNA-1,4,6-TRIENE-3,20-DIONE ACETATE; 6-chloro-3,20-dioxo-1beta,2beta-dihydro-3''H-cyclopropa[1,2]pregna-4,6-dien-17-yl acetate; acetic acid (8R,9S,10S,13S,14S,17R)-17-acetyl-6-(S)-chloro-10,13-dimethyl-3-(R)-oxo-1,2,3,8,9,10,11,12,13,14,15,16,17,20-tetradecahydro-cyclopropa[1,2]cyclopenta[a]phenanthren-17-yl ester